652990-08-4

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 201677-59-0 N-[5-((1R)-2-bromo-1-hydroxyethyl)-2-(phenylmethoxy)phenyl]carboxamide 

Downstream Products

• 860032-54-8 N-{5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-2-hydroxy-phenyl}-formamide 
• 860032-38-8 N-{5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-benzyloxy-phenyl}-formamide 
• 804518-04-5 (R)-N-(2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl)ethylamine monohydrochloride 
• 1361953-18-5 2-((S)-1-{9-[(R)-2-(4-benzyloxy-3-formylaminophenyl)-2-(tert-butyldimethylsilanyloxy)ethylamino]nonyl}pyrrolidin-3-yl)-2,2-diphenylacetamide 
• 1159340-48-3 [5-((1R)-2-[(2-{4-[2-(1-adamantyl)ethoxy]phenyl}ethyl)-amino]-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-(benzyloxy)phenyl]-formamide 
• 950679-23-9 N-{2-(benzyloxy)-5-[(1R)-2-({2-[4-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethoxy)phenyl]ethyl}amino)-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl]phenyl}formamide 
• 950679-00-2 N-{2-(benzyloxy)-5-[(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]phenyl}formamide 
• 865589-91-9 2-(3-{(2R)-2-[((2R)-2-[3-(acetylamino)-4-(benzyloxy)phenyl]-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]propyl}-phenyl)-N-1-adamantylacetamide 
• 865589-75-9 2-(3-{2-[(2R)-2-(4-benzyloxy-3-formylaminophenyl)-2-(tert-butyl-dimethylsilanyloxy)ethylamino]-2-methylpropyl}phenyl)-N-(3,4-dichlorobenzyl)acetamide 
• 865590-62-1 3-{(2R)-2-[(2R)-2-(4-benzyloxy-3-formylaminophenyl)-2-(tert-butyidimethylsilanyloxy)ethylamino]propyl}benzoic acid benzyl ester 
• 865589-95-3 benzyl 3-{2-[((2R)-2-[4-(benzyloxy)-3-(formylamino)phenyl]-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}benzoate 
• 849540-59-6 N-[5-((R)-2-{2-[4-((S)-2-amino-2-phenylethylamino)phenyl]-ethylamino}-1-(tert-butyldimethylsilanyloxy)ethyl)-2-benzyloxyphenyl]formamide 
• 849540-56-3 N-[5-((R)-2-{2-[4-((S)-2-hydroxy-2-phenylethylamino)phenyl]-ethylamino}-1-(tert-butyldimethylsilanyloxy)ethyl)-8-benzyloxyphenyl]formamide 
• 956235-32-8 3-[{(13R)-13-[4-(benzyloxy)-3-(formylamino)phenyl]-15,15,16,16-tetramethyl-4,14-dioxa-11-aza-15-silaheptadec-1-yl}(methyl)amino]benzamide 

Relevant academic research and scientific papers

Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity

This invention provides compounds of formula I: wherein R1, R2, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

This invention provides compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

COMPOUNDS HAVING BETA-AGONIST ACTIVITY

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

CHEMICAL PROCESS AND NEW CRYSTALLINE FORM

The present invention relates to the preparation of a ?2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I): in particular a crystalline monohydrochloride salt. The inventi

Azabicycloalkane compounds

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

Biphenyl derivatives

This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST

The invention provides a crystalline salt form of a novel β2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the crystalline form, formulations containing the pharmaceutical compositions, methods of using th

DIARYLMETHYL AND RELATED COMPOUNDS

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c, and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.